Search results for "Interactions"

showing 10 items of 1963 documents

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Executive and arousal vigilance decrement in the context of the attentional networks: The ANTI-Vea task

2018

Vigilance is generally understood as the ability to detect infrequent critical events through long time periods. In tasks like the Sustained Attention to Response Task (SART), participants tend to detect fewer events across time, a phenomenon known as vigilance decrement. However, vigilance might also involve sustaining a tonic arousal level. In the Psychomotor Vigilance Test (PVT), the vigilance decrement corresponds to an increment across time in both mean and variability of reaction time. New Method: The present study aimed to develop a single task Attentional Networks Test for Interactions and Vigilance executive and arousal components (ANTI-Vea) to simultaneously assess both components…

AdultMaleAdolescentmedia_common.quotation_subjectVIGILANCE DECREMENTNeuropsychological TestsPhasic alertnessbehavioral disciplines and activities050105 experimental psychologyArousalCIENCIAS SOCIALESExecutive FunctionYoung Adult03 medical and health sciences0302 clinical medicineSingle taskReaction TimeHumansAttention0501 psychology and cognitive sciencesAROUSAL VIGILANCEmedia_commonPsychomotor learningPSYCHOMOTOR VIGILANCE TEST (PVT)General Neuroscience05 social sciencesOtras PsicologíaResponse biasPsicologíaSUSTAINED ATTENTION TO RESPONSE TASK (SART)EXECUTIVE VIGILANCEFemaleArousalPsychologyPsychomotor Performance030217 neurology & neurosurgeryATTENTIONAL NETWORKS TEST-INTERACTIONS (ANT-I)Cognitive psychologyVigilance (psychology)Journal of Neuroscience Methods
researchProduct

Dose-dependent absorption and elimination of cefadroxil in man.

1991

The pharmacokinetic behaviour of cefadroxil was dose-dependent in healthy male volunteers following the oral administration of single doses of 5, 15, and 30 mg.kg-1. As the dose of cefadroxil increased from 5 to 15 and 30 mg.kg-1, the peak plasma concentrations, normalized to 5 mg.kg-1, decreased significantly from 15.1 to 10.7 and 7.6 mg.l-1, while the corresponding normalized areas under the plasma concentration-time curves from 0 to 2 h decreased significantly from 1258 to 946 and 801 min.mg.l-1. When the same subjects were given 5 mg.kg-1 of cefadroxil together with 45 mg.kg-1 of cephalexin, the absorption of cefadroxil was slowed to a similar or greater extent than with the high dose o…

AdultMaleAdolescentmedicine.drug_classMetabolic Clearance RateAntibioticsAbsorption (skin)PharmacologyKidneyAbsorptionPharmacokineticsOral administrationReference ValuesmedicineHumansPharmacology (medical)Drug InteractionsPharmacologyCephalexinDose-Response Relationship DrugChemistryCefadroxilKidney metabolismGeneral MedicineDrug interactionDose–response relationshipCefadroxilmedicine.drugEuropean journal of clinical pharmacology
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability

2008

Previous in vitro studies using Caco-2 cell monolayers suggested a possible interaction between green and black tea and folic acid at the level of intestinal absorption. The main purpose of the present study was to investigate a possible pharmacokinetic interaction between tea and folic acid in healthy volunteers. In an open-labeled randomized cross-over study, the pharmacokinetic interaction between tea and folic acid (0.4 mg and 5 mg) was investigated in healthy volunteers. Water was used as the reference drink. Subjects ingested 0.4 mg folic acid tablets with water, green or black tea (0.3 g extract/250 ml) or 5 mg folic acid tablets with water or green tea (0.3 g extract/250 ml). Blood …

AdultMaleBiological AvailabilityPharmaceutical SciencePharmacologyIntestinal absorptionFood-Drug InteractionsFolic AcidPharmacokineticsIn vivoHumansPharmacology (medical)Black teaImmunoassayPharmacologyCross-Over StudiesDose-Response Relationship DrugTeaChemistryfood and beveragesGeneral MedicineMiddle AgedCrossover studyBioavailabilityDose–response relationshipFolic acidArea Under CurveLuminescent MeasurementsVitamin B ComplexFemaleBiopharmaceutics & Drug Disposition
researchProduct

The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans.

2017

Hypoxemia can be life-threatening, both acutely and chronically. Because hypoxemia causes vascular dysregulation that further restricts oxygen availability to tissue, it can be pharmacologically addressed. We hypothesized that theophylline can be safely combined with the β2-adrenergic vasodilator bambuterol to improve oxygen availability in hypoxemic patients. Ergogenicity and hemodynamic effects of bambuterol and theophylline were measured in rats under hypobaric and normobaric hypoxia (12% O2). Feasibility in humans was assessed using randomized, double-blind testing of the influence of combined slow-release theophylline (300 mg) and bambuterol (20 mg) on adverse events (AEs), plasma K+,…

AdultMaleCombination therapyPhysiologyAdrenergicBiological Availability030204 cardiovascular system & hematologyPharmacologyHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineTheophyllinePhysiology (medical)Physical Conditioning AnimalmedicineTerbutalineAnimalsHumansTheophyllineDrug InteractionsBambuterolHypoxiaPharmacologybusiness.industryHemodynamicsGeneral MedicineDrug interactionHypoxia (medical)RatsBlood pressureTreatment OutcomeAnesthesiaFemalemedicine.symptomSafetybusiness030217 neurology & neurosurgerymedicine.drugHalf-LifeCanadian journal of physiology and pharmacology
researchProduct

Atenolol interaction with aspirin, allopurinol, and ampicillin.

1983

Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered…

AdultMaleCombination therapyUrinary systemAllopurinolPhysical ExertionAllopurinolBiological AvailabilityBlood PressurePharmacologyPropanolaminesHeart RateAmpicillinmedicineHumansPharmacology (medical)Drug Interactionscardiovascular diseasesPharmacologyAspirinAspirinChemistryAtenololBioavailabilityKineticsBlood pressureAtenololAmpicillinFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man

1976

The effect of repeated administration of tolbutamide on the elimination and anticoagulant action of a single oral dose of dicoumarol 600 mg was studied in four healthy male subjects using a crossover design. In all subjects the plasma concentration of dicoumarol in the postabsorptive phase was lower during concomitant tolbutamide treatment. However, the subjects differed with respect to the elimination kinetics of dicoumarol and the effect of tolbutamide on some of the measured pharmacokinetic paramaters. In two subjects dicoumarol was eliminated by apparent first-order kinetics. Tolbutamide led to a pronounced increase in the elimination rate and a shift in the plasma concentration-respons…

AdultMaleDicumarolmedicine.medical_specialtymedicine.drug_classTolbutamidePharmacologySingle oral dosechemistry.chemical_compoundTolbutamidePharmacokineticsInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyAnticoagulantGeneral MedicineDicoumarolCoumarinCrossover studyPharmacokinetic analysisEndocrinologychemistryHalf-LifeProtein Bindingmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Plasticity of brain wave network interactions and evolution across physiologic states

2015

Neural plasticity transcends a range of spatio-temporal scales and serves as the basis of various brain activities and physiologic functions. At the microscopic level, it enables the emergence of brain waves with complex temporal dynamics. At the macroscopic level, presence and dominance of specific brain waves is associated with important brain functions. The role of neural plasticity at different levels in generating distinct brain rhythms and how brain rhythms communicate with each other across brain areas to generate physiologic states and functions remains not understood. Here we perform an empirical exploration of neural plasticity at the level of brain wave network interactions repre…

AdultMaleNerve netCognitive NeuroscienceNeuroscience (miscellaneous)Sensory systemPlasticityCognitive neurosciencelcsh:RC321-571Young AdultCellular and Molecular NeuroscienceNeuroplasticitymedicineHumanslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal ResearchSlow-wave sleepCerebral CortexNetwork physiologySleep StagesNeuronal PlasticityBrain WaveBrain wave interactions; Network physiology; Neural plasticity; Sleep; Time delay stability; Adult; Brain Waves; Cerebral Cortex; Female; Humans; Male; Nerve Net; Neuronal Plasticity; Sleep; Young Adult; Neuroscience (miscellaneous); Cellular and Molecular Neuroscience; Sensory Systems; Cognitive NeuroscienceNetwork dynamicsBrain WavesSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Sensory Systemsbrain wave interactionsmedicine.anatomical_structureBrain wave interactionFemaletime delay stabilityNerve NetSensory SystemPsychologySleepNeuroscienceHumanNeuroscienceneural plasticityFrontiers in Neural Circuits
researchProduct